Posted On: 01/28/2016 11:36:08 AM
Post# of 72444
A lot of Movers in the next 5 months.
Just amazing imo. $1.16? even more amazing!
Which 1 is next?
We are looking forward (See Forward-Looking Statements Below) to our fiscal year end of June 30, 2016 and we hope to announce/have announced:
Start of Kevetrin advanced study in ovarian cancer.
Start of Brilacidin ABSSSI Phase 3
Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)
Top line data on Kevetrin Phase 1 trial for advanced solid tumors
Top line data on Prurisol Phase 2 trial for chronic plaque psoriasis
Interim analysis for Brilacidin Phase 2 trial for Oral Mucositis
Start of Retinoblastoma program, formulation and toxicity studies
Additional ototoxicity studies with Brilacidin in different concentrations
Gram- negative and anti-fungal progress
Submission of grant application for study of Kevetrin in Pancreatic cancer with renowned hospital.
Just amazing imo. $1.16? even more amazing!
Which 1 is next?
We are looking forward (See Forward-Looking Statements Below) to our fiscal year end of June 30, 2016 and we hope to announce/have announced:
Start of Kevetrin advanced study in ovarian cancer.
Start of Brilacidin ABSSSI Phase 3
Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)
Top line data on Kevetrin Phase 1 trial for advanced solid tumors
Top line data on Prurisol Phase 2 trial for chronic plaque psoriasis
Interim analysis for Brilacidin Phase 2 trial for Oral Mucositis
Start of Retinoblastoma program, formulation and toxicity studies
Additional ototoxicity studies with Brilacidin in different concentrations
Gram- negative and anti-fungal progress
Submission of grant application for study of Kevetrin in Pancreatic cancer with renowned hospital.
(0)
(0)
